Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
22 Results for "
GPIIb-IIIa antagonist
" in MedChemExpress (MCE) Product Catalog:
Products (22)
22 Results for "GPIIb-IIIa antagonist" in MCE Product Catalog:
Target:
Research Areas:
(±)-Clopidogrel bisulfate is a platelet P2Y12 receptor inhibitor and an adenosine diphosphate (ADP) receptor antagonist. (±)-Clopidogrel bisulfate inhibits the binding of ADP to its receptors on the membranes of platelet cells, and blocks ADP-mediated activation of the glycoprotein GPIIb/IIIa complex. (±)-Clopidogrel bisulfate reduces vascular inflammation and angiotensin II induced-abdominal aortic aneurysm progression. (±)-Clopidogrel bisulfate has anti-inflammatory effects .
Target:
Research Areas:
Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
Cat. No.: HY-117177
CAS No.: 170902-52-0
Target:
Research Areas:
XV459 is an orally active platelet GPIIb/IIIa receptor antagonist. XV459 blocks all agonist induced platelet aggregation by binding to platelet GPIIb/IIIa receptors. XV459 can significantly prolong occlusion time, reduce thrombus weight, and maintain blood flow. XV459 can be used for anti thrombotic research .
Cat. No.: HY-10304
CAS No.: 163250-90-6
Target:
Research Areas:
Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
Cat. No.: HY-10306
CAS No.: 183547-57-1
Target:
Research Areas:
Gantofiban is a GPIIb/IIIa integrin receptor antagonist. By binding to this receptor, Gantofiban can effectively inhibit platelet aggregation, thereby exerting its antithrombotic effect .
Cat. No.: HY-169827
CAS No.: 167364-01-4
Target:
Research Areas:
EMD-132338 is a GPIIb/IIIa (αIIbβ3) antagonist that inhibits platelet aggregation. EMD-132338 can be utilized in antithrombosis research .
Cat. No.: HY-122230
CAS No.: 220386-65-2
Target:
Research Areas:
UR-3216 is a selective, and orally active platelet surface glycoprotein (GPIIb/IIIa) receptor antagonist. UR-3216 has the potential for cardiovascular diseases research .
Cat. No.: HY-10315
CAS No.: 198958-88-2
Synonyms: RWJ-53308
Target:
Research Areas:
Elarofiban (RWJ-53308) is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban has the potential for platelet mediated thrombotic disorders research .
Cat. No.: HY-120080
CAS No.: 220386-56-1
UR-2922 is a platelet GPIIb/IIIa antagonist with antiplatelet aggregation and cardiovascular disease inhibition activities. UR-2922 has high affinity for human platelet receptors and has good pharmacokinetic properties, and can be used to inhibit cardiovascular diseases.
Cat. No.: HY-19248
CAS No.: 165948-72-1
Target:
Research Areas:
ME-3277 is a potent GPIIb/IIIa antagonist. ME-3277 reduces cerebral infarction without enhancing intracranial hemorrhage in photothrombotic occlusion of rabbit middle cerebral artery (MCA). ME-3277 can be used for the acute cerebral infarction research .
Cat. No.: HY-10315A
CAS No.: 198958-89-3
Target:
Research Areas:
Elarofiban diTFA is the salt form of Elarofiban (HY-10315) with two TFA. Elarofiban diTFA is a nonpeptide, orally active antagonist for fibrinogen receptor αIIbβ3 (GPIIb/IIIa), with an IC50 of 0.15 nM. Elarofiban diTFA has the potential for platelet mediated thrombotic disorders research .
Category:
Target:
Cat. No.: HY-107867S1
Cat. No.: HY-125373
CAS No.: 183745-58-6
Target:
Research Areas:
L-767685, the ethyl ester prodrug of L-767679 (HY-116925), is a non-peptide glycoprotein IIb/IIIa receptor (GPIIb-IIIa receptor) antagonist. L-767679 has a potent anti-platelet aggregation effect. L-767685 can be used for research on antithrombosis .
Cat. No.: HY-107867S2
CAS No.: 1246814-55-0
Cat. No.: HY-106394
CAS No.: 138297-15-1
Target:
Research Areas:
TP-9201 is a platelet glycoprotein (GP) IIb/IIIa receptor antagonist. TP-9201 inhibits the interaction between GPIIb/IIIa and fibrinogen, thereby suppressing platelet aggregation. TP-9201 exhibits similar inhibitory activity on adenosine diphosphate (ADP) (HY-W010918)-induced platelet aggregation in humans, baboons, and dogs (IC50 = 1-3 μM), while showing lower activity in rabbits (IC50 = 45 μM) and rats (IC50 = 20 μM). TP-9201can be used in studies related to the prevention of rethrombosis after arterial thrombolysis .
Cat. No.: HY-119158
CAS No.: 1476847-58-1
Research Areas:
VU0652925, an analog of BMS986120, is a PAR4 antagonist, with IC50 values of 43 pM and 39.2 pM for PAC1 and P-selectin, respectively. VU0652925 is able to suppress GPIIbIIIa activation .
Cat. No.: HY-10304AR
CAS No.: 163250-91-7
Target:
Research Areas:
Orbofiban acetate (Standard) is the analytical standard of Orbofiban acetate (HY-10304A). This product is intended for research and analytical applications. Orbofiban acetate is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.
Cat. No.: HY-P0038
CAS No.: 138199-64-1
Synonyms: L-367073
Target:
Research Areas:
Cat. No.: HY-167848
CAS No.: 153345-74-5
Synonyms: XL-118
Target:
Research Areas:
DMP-728 free base (XL-118) is a highly potent and selective GPIIb/IIIa antagonist with antiplatelet and antithrombotic activities. DMP-728 free base can inhibit ADP-induced human platelet aggregation in vitro, with an IC50 of 46 nmol/L, and can significantly reduce the interaction between fibrinogen and human platelets or Binding of purified human GPIIb/IIIa receptors. DMP-728 free base exhibits dose-dependent antiplatelet effects in anesthetized mongrel dogs, effectively inhibiting ADP-induced platelet aggregation and prolonging template bleeding time .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
